Pernix Therapeutics Holdings, Inc. / Cypress Pharmaceuticals, Inc. and Hawthorn Pharmaceuticals, Inc.
2012 · Acquisition/Merger · $102M · Complete
Announcement Sentiment
79
Strongly positive
Pernix acquired Cypress Pharmaceuticals (private generics) and Hawthorn Pharmaceuticals for up to $102M ($52M cash + $34M equity upfront, plus contingent payments). Strategic doubling-down in specialty pharmaceuticals.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Stalled
Assessment window: 10yr post-close.
Key facts
AnnouncedNov 14, 2012
ClosedJan 02, 2013
Deal value$102M
Deal typeAcquisition/Merger
Therapeutic areaMulti-therapeutic generics and branded specialty
IndicationsMulti-therapeutic generics and branded specialty